Cancer Treatment Reviews
Volume 36, Issue 5 , Pages 384-392 , August 2010

Advanced gastric cancer – Slow but steady progress

  • Derek G. Power
    • ,
  • David P. Kelsen
    • ,
  • Manish A. Shah

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, H910, NY 10065, USA. Tel.: +1 212 639 3113; fax: +1 212 717 3320.

Received 18 December 2009 ,Revised 22 January 2010 ,Accepted 26 January 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249
  3. Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):34–36
  4. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–816
  5. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007;12(3):253–270
  6. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683
  7. Catalano V, Graziano F, Santini D, D’Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. Br J Cancer. 2008;99(9):1402–1407
  8. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–168
  9. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37–41
  10. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–591
  11. Scheithauer W, Kornek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. In: Second international conference on biology, prevention and treatment of GI malignancy, Koln, Germany, 68, 1995. [abstract].
  12. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–2909
  13. Icli F, Celik I, Aykan F, Uner A, Demirkazik A, Ozet A, et al. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish oncology group. Cancer 1998;83(12):2475–80.
  14. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71(12):3813–3818
  15. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). J Clin Oncol. 2003;21(1):54–59
  16. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002;13(10):1568–1575
  17. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol. 2000;18(14):2648–2657
  18. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–267
  19. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004
  20. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–1442
  21. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). In: Annual proceedings. Orlando, FL, USA: American Society of Clinical Oncology; 2008 [abstract LBA4513].
  22. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46
  23. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450–1457
  24. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221
  25. Ridwelski K, Fahlke J, Kettner E, Schmidt C, Keilholz U, Quietzsch D, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study. Amercan society of clinical oncology, Chigago, IL, USA, 2008 [abstract 4512].
  26. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673
  27. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–4997
  28. Ajani JA, Rodriquez W, Bodoky G, Moiseyenko VM, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. In: Annual proceedings. Orlando, FL, USA: American Society of Clinical Oncology; May 29th–June 2nd, 2009 [abstract #4511].
  29. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Combination chemotherapies in advanced gastric cancer: an updated systematic review and meta-analysis. Chicago, IL, USA: American Society of Clinical Oncology; 1–5 June 2007 [abstract 4555].
  30. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18(10):1673–1679
  31. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882–1887
  32. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;12:12
  33. Shah MA, Stoller R, Shibata S, Kemeny M, Mehrotra B, Ritch PS, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil(mDCF) versus DCF with growth factor support(GCSF) in metastatic gastroesophageal adenocarcinoma(GE) In: Gastrointestinal cancers symposium. Orlando, FL: American Society of Clinical Oncology; 2010 [abstract #170].
  34. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. In: Annual proceedings. American Society of Clinical Oncology; 2005 [abstract 4014].
  35. Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol 2001;28(6 Suppl. 18):30–5.
  36. Van Cutsem E, Kang K, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). In: Annual proceedings. Orlando, FL, USA: American Society of Clinical Oncology; May 29th–June 2nd, 2009 [abstract #LBA 4509].
  37. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. In: Annual proceedings. Orlando, FL: American Society of Clinical Oncology; 29 May–2 June, 2009 [abstract #4556].
  38. Bang Y, Kang Y, Kang WK, Boku N, Chung H, Lanzalone S, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. Chicago, IL, USA: American Society of Clinical Oncology; 2008 [abstract 4603].
  39. Enzinger PC, Fidias P, Stuart K, al e. Phase II study of bevacizumab and docetaxel (AVATAX) in metastatic esophageal and gastric cancer. Ann Oncol 2006;17(ix310):1078PDa.
  40. Enzinger PC, Ryan DP, Regan EM, Lehman N, Abrams TA, Hezel AF, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Chicago, IL, USA: American Society of Clinical Oncology; 2008 [abstract 4552t].
  41. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100(2):298–304
  42. Stein A, Al-Batran SE, Arnold D, Peinert S, Siewczynski R, Schmoll HJ. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. In: Gastrointestinal cancers symposium, 2007 [abstract #47].
  43. Jhawer M, Tse A, Ilson DH, Robinson E, Zheng J, Randazzo J, et al. Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma. In: Gastrointestinal cancer symposium, San Francisco, CA, USA, 15–17 January, 2009 [abstract 10].
  44. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510–517
  45. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;22:22
  46. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–5206
  47. Sun W, Powell ME, O’Dwyer P, Ansari RH, Benson AB. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). Chicago, IL, USA: American Society of Clinical Oncology; 1–5 June, 2008 [abstract 4535].
  48. Lordick F, Ott K, Weitz J, Jager D. The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther. 2008;8(9):1407–1415
  49. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395–2403
  50. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(5):886–891
  51. Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;107(2):275–279
  52. Rothenberg ML. Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer 2004;4(Suppl. 1):S16–21.
  53. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Orlando, FL: American Society of Clinical Oncology; May 29th–June 2nd, 2009 [abstract 4540].
  54. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009;10(9):903–912
  55. Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007;37(12):936–941
  56. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol. 2008;61(4):631–637
  57. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60(2):159–179
  58. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50
  59. Vansteenkiste J. Improving patient management in metastatic non-small cell lung cancer. Lung Cancer 2007;57 (Suppl. 2):S12–7.
  60. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric cancer. 2006;9(1):14–18
  61. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007;27(4C):2667–71.
  62. Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli-Bosc FX. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol. 2009;4:4
  63. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D’Argento E, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric cancer. 2007;10(2):104–111
  64. Lee KW, Kim JH, Yun T, Song EK, Na, II, Shin H, et al. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. J Korean Med Sci 2007;22(Suppl. 21):S115–21.
  65. Rosati G, Bilancia D, Germano D, Dinota A, Romano R, Reggiardo G, et al. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. Ann Oncol 2007;18(Suppl. 6):vi128–32.
  66. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008;63(1):1–8
  67. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(10):1013–1018
  68. Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol. 2008;19(6):1135–1140
  69. Schmid KE, Kornek GV, Schull B, Raderer M, Lenauer A, Depisch D, et al. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie. 2003;26(3):255–258
  70. Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, et al. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2009;63(3):433–439
  71. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric cancer. 2006;9(3):203–207
  72. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17(10):3270–3275
  73. Schønnemann KR, Bjerregaard JK, Jensen HA, Vestermark LW, Højberg L, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. In: Gastrointestinal cancers symposium, Orlando, FL, 2009 [abstract #73].
  74. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, et al. ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer–final results of a multicentre phase II trial by the AGITG. In: Annual proceedings. Chicago, IL: American Society of Clinical Oncology; 2008 [abstract #15554].
  75. Chau I, Ashley S, Cunningham D. Validation of the royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol. 2009;26:26
  76. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61(2):301–307
  77. Pozzo C, Ohashi Y, Projecobot G. Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. Orlando, FL, USA: American Society of Clinical Oncology; 2009 [abstract 4550].
  78. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan clinical oncology group (JCOG) study. Jpn J Clin Oncol. 2004;34(11):654–659
  79. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol. 2004;22(15):3099–3103
  80. Bohanes PO, Courvoisier D, Perneger T, Morel P, Huber O, Roth AD. Survival predictors in second-line chemotherapy for metastatic gastric cancer. Chicago, IL, USA: American Society of Clinical Oncology; 2009 [abstract e15575].
  81. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol. 1994;12(12):2687–2693
  82. Ji SH, Lim do H, Yi SY, Kim HS, Jun HJ, Kim KH, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009;9(110):110.
  83. Kim S, Hwang M, Park YS, Park S, Kim YH, Ryu K, et al. Prognostic impact of response to second-line chemotherapy on overall survival of patients with advanced gastric cancer. Chicago, IL, USA: American Society of Clinical Oncology; 2009 [Abstract e15551].
  84. Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH, et al. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol. 2006;57(3):289–294
  85. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 2005;17(2):81–90
  86. Ichikawa W, Sasaki Y. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol. 2006;17(11):1665–1672
  87. Ribeiro MM, Sarmento JA, Sobrinho Simoes MA, Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer. 1981;47(4):780–784
  88. Suriano G, Mulholland D, de Wever O, Ferreira P, Mateus AR, Bruyneel E, et al. The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion. Oncogene. 2003;22(36):5716–5719
  89. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;19:19
  90. Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115(10):2071–2080
  91. Jhawer MP, Kindler HL, Wainberg ZA, Hecht JR, Kerr RO, Ford JM, et al. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study. Chicago, IL, USA: American Society of Clinical Oncology; 2008 [abstract 4572].
  92. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69–79
  93. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008;98(4):832–839
  94. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51(8):1371–1379
  95. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2009;27(17):2863–2873
  96. Al-Batran SE, Wirtz RM, Pauligk C, Steinmetz K, Probst S, Hartmann JT, et al. Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: results from the FLO versus FLP gastric cancer phase III trial of the AIO. In: Annual proceedings. Chicago, IL: American Society of Clinical Oncology; 2008 [abstract #4544].
  97. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26(13):2118–2123
  98. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805
  99. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14(7):2012–2018
  100. Shah MA, Yeung H, Coit D, Trocola R, Ilson DH, Randazzo J, et al. A phase II study of preoperative chemotherapy with irinotecan(CPT) and cisplatin(CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome. In: Annual proceedings. Orlando, FL: American Society of Clinical Oncology; 2007 [abstract #4502].
  101. Hamaguchi T, Shirao K, Yamamichi N, Hyodo I, Koizumi W, Seki S, et al. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the gastrointestinal oncology group of the Japan clinical oncology group, JCOG 9207 trial. Jpn J Clin Oncol. 2008;38(6):432–437
  102. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, et al. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drug. 1999;10(8):729–733
  103. Park SH, Kim YS, Hong J, Park J, Nam E, Cho EK, et al. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drug. 2008;19(3):303–307
  104. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, et al. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(1):157–165
  105. Hartmann JT, Pintoffl JP, Al-Batran SE, Quietzsch D, Meisinger I, Horger M, et al. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. Onkologie. 2007;30(5):235–240
  106. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J Clin Oncol. 2009;39(11):713–719
  107. Matsuda G, Kunisaki C, Makino H, Fukahori M, Kimura J, Sato T, et al. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res. 2009;29(7):2863–2867
  108. Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, et al. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. J Oncol Pharm Pract. 2009;15:15
  109. Leary A, Assersohn L, Cunningham D, Norman AR, Chong G, Brown G, et al. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2008;23:23
  110. Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, et al. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol. 2008;38(9):589–595
  111. Suzuki S, Harada N, Takeo Y, Tanaka S, Hayashi T, Suzuki M, et al. Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer. Gan To Kagaku Ryoho. 2007;34(13):2245–2248
  112. Sun Q, Hang M, Xu W, Mao W, Hang X, Li M, et al. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol. 2009;39(12):791–796
  113. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol. 2008;31(2):151–156
  114. Yoshida T, Yoshikawa T, Tsuburaya A, Kobayashi O, Hasegawa S, Osaragi T, et al. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer. Anticancer Res 2006;26(2B):1595–8.
  115. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, et al. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol. 2007;37(10):744–749
  116. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer. 2005;92(10):1850–1854
  117. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, et al. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol. 2009;64(2):301–306
  118. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, et al. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. 2106). Am J Clin Oncol 2005;28(6):581–5.
  119. Miyamoto H, Yoshida M, Yamanouchi T, Kanda K, Zinnouchi K, Kiyozumi T, et al. Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice. Gan To Kagaku Ryoho. 2009;36(8):1293–1297

PII: S0305-7372(10)00020-4

doi: 10.1016/j.ctrv.2010.01.005

Cancer Treatment Reviews
Volume 36, Issue 5 , Pages 384-392 , August 2010

Article Tools

* Image Usage & Resolution